Colesevelam (As Hydrochloride)
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Colesevelam (As Hydrochloride) |
| DrugBank ID | DB00930 |
| Brand Names (EU) | Cholestagel |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 93.37% |
Approved Indication (EMA)
Cholestagel co-administered with a 3-hydroxy-3-methyl-glutaryl-coenzyme-A (HMG-CoA)-reductase inhibitor (statin) is indicated as adjunctive therapy to diet to provide an additive reduction in low-density-lipoprotein-cholesterol (LDL-C) levels in adult patients with primary hypercholesterolaemia who are not adequately controlled with a statin alone. Cholestagel as monotherapy is indicated as adjunctive therapy to diet for reduction of elevated total cholesterol and LDL-C in adult patients with pr
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | gout | 93.37% | DL |
| 2 | congestive heart failure | 89.76% | DL |
| 3 | acute pulmonary heart disease | 88.61% | DL |
| 4 | autosomal dominant familial hematuria-retinal arteriolar tortuosity-contractures syndrome | 87.09% | DL |
| 5 | brain small vessel disease 1 with or without ocular anomalies | 86.91% | DL |
| 6 | infectious otitis media | 86.33% | DL |
| 7 | diabetic nephropathy | 86.16% | DL |
| 8 | phosphorus metabolism disease | 84.83% | DL |
| 9 | middle ear cholesterol granuloma | 84.80% | DL |
| 10 | otosalpingitis | 84.60% | DL |
| 11 | endocardial fibroelastosis | 84.49% | DL |
| 12 | middle ear disease | 84.25% | DL |
| 13 | allergic otitis media | 84.12% | DL |
| 14 | non-suppurative otitis media | 84.04% | DL |
| 15 | chronic otitis media | 83.89% | DL |
| 16 | endocarditis | 83.69% | DL |
| 17 | epiglottitis | 83.45% | DL |
| 18 | suppurative otitis media | 83.24% | DL |
| 19 | dyspepsia | 83.12% | DL |
| 20 | HIV infectious disease | 79.90% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.